Precision medicine is the practise of identifying a patient's hereditary risk of developing hypertension and possibly deadly cardiovascular events over their lifetime using information from their DNA. Using genomic data from close to 500,000 people of various racial and cultural origins, a study developed a blood pressure genetic risk score that quantifies a person's hereditary propensity for high blood pressure. According to the study at the UAB Division of Cardiovascular Disease, often occurring alterations in our DNA constitute the composite genetic risk score for hypertension in an individual. The risk for hypertension and cardiac diseases throughout our lifetime because of these often occurring DNA mutations that are present at birth, and this risk are determined by our genetic risk score. Having a personalised evaluation of a person's risk of fatal cardiac events is important in the present era of precision cardiovascular medicine because it enables us to concentrate our efforts on preventing fatal heart events through a personalised strategy based on their genetic risk. It has not historically been very successful for genetic medicine to involve people from underrepresented groups in its study. One of this study's greatest advantages is the inclusion of participants from underrepresented groups. Future research on the impact of genetic risk score dissemination to enhance blood pressure control and inspire long-term lifestyle changes in younger people with high genetic risk of cardiac events is one of the study's potential ramifications. Over 50,000 people in the Action to Control Cardiovascular Risk in Diabetes trial database and the All of Us Research Program, both funded by the National Institutes of Health, were used to cross-verify the study's findings.